Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial
- Authors:
- AM Piskorz, KK Lin, J Morris, E Mann, A Oza, RL Coleman, DM O'Malley, M Friedlander, JM Cragun, L Ma, H Giordano, M Raponi, IA McNeish, E Swisher, JD Brenton
- Journal:
- EUROPEAN JOURNAL OF CANCER
- Citation info:
- 69:S123-S123
- Publication date:
- 1st Aug 2016
- Full text
- DOI